News: Portfolio 2008

CELLUMEN AND MITSUBISHI TANABE PHARMA CORPORATION COLLABORATE IN DISCOVERY TOXICOLOGY

Partnership will aim to enable earlier discovery of toxicity for drugs in development

Pittsburgh, PA, August 19, 2008 —Cellumen, Inc., a discovery toxicology company, today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity
early in the drug development process.

 

“We’re pleased to announce this collaboration with MTPC,” says D. Lansing Taylor, PhD, CEO
of Cellumen. “By working together to develop biomarker panels, we hope to identify toxic
liabilities much earlier in the drug development process than currently exists in the marketplace.
Our ultimate goal is to enable MTPC to prioritize its lead drug series.”

 

Cellumen is focused on decreasing the drug attrition rate due to toxicity. The company’s